Soficabtagene Geleucel

索菲基杰仑赛

Report date: 2026/01/23 18:05:27

Base Information

Drug NameSoficabtagene Geleucel
Drug Alias NameAnti-CD7 Allogeneic CAR-T CellsWU-CART-007
ClassificationCell and gene therapy > Cell therapy > Source of cells > Leukocyte-derivedCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[5] 
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralSezary Syndrome +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWugen Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington UniversityWashington University School Of MedicineWugen Inc +[4] 
Inactive CompaniesN/A
Active IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralSezary Syndrome +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A